Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Study of Milatuzumab Administered Subcutaneously in Patients With Active Systemic Lupus Erythematosus (SLE)

NCT01845740 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT01845740
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01845740 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Study of Milatuzumab Administered Subcutaneously in Patients With Active Systemic Lupus Erythematosus (SLE)
Lead sponsor
Gilead Sciences
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2007
Completion date
June 30, 2009
Enrollment
22 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lupus erythematosus, cutaneous, lupus erythematosus, discoid, lupus erythematosus, systemic, lupus nephritis, lupus vasculitis, central nervous system